Company Description
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs.
It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses.
The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein.
Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem.
The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017.
Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Country | NY |
| Founded | 2017 |
| IPO Date | Dec 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Alan D. Horsager Ph.D. |
Contact Details
Address: 420 Lexington Avenue, Suite 300 New York, New York 10170 United States | |
| Phone | (212) 479-2513 |
| Website | scopusbiopharma.com |
Stock Details
| Ticker Symbol | SCPS |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.50 |
| CIK Code | 0001772028 |
| CUSIP Number | 809171101 |
| ISIN Number | US8091711015 |
| Employer ID | 82-1248020 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Ira Scott Greenspan | Senior Advisor and Director |
| Robert J. Gibson | Vice Chairman, Secretary and Treasurer |
| Dr. Alan D. Horsager Ph.D. | President?of?Immuno-Oncology and President and Chief Executive Officer of Duet BioTherapeutics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 9, 2024 | 1-Z | Filing |
| Jan 19, 2024 | 15-12G | Securities registration termination |
| Aug 18, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 8-K | Current Report |
| Aug 11, 2023 | 10-Q | Quarterly Report |
| Jul 21, 2023 | DEF 14A | Other definitive proxy statements |
| Jun 28, 2023 | PRER14A | Filing |
| May 12, 2023 | 10-Q | Quarterly Report |
| Apr 28, 2023 | 10-K/A | [Amend] Annual report |
| Apr 14, 2023 | 10-K | Annual Report |